Loading
When a blood test says 'cancer signal, origin unclear', a FAPI PET scan may find it where FDG cannot.
When a blood test reports a cancer signal of unclear origin, this idea sends the patient for FAPI PET/CT rather than FDG PET as the first-line work-up. Many MCED-positive patients have no cancer found on standard imaging, which creates anxiety and cost, whereas FAPI PET is more sensitive than FDG in pancreatic, gastric, low-grade and peritoneal disease, exactly the cancers MCED promises to catch, and has low background in liver, brain and bowel. The test is a prospective diagnostic study nested in a Galleri deployment such as the NHS or a PATHFINDER-like cohort, randomising FDG versus FAPI PET. Speculative in maturity, it addresses the bottleneck The hardest cancers are found late and is linked from the ideas on a 28-day MCED-positive resolution pathway and whole-population interception.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares FAPI PET, FAP, Pancreatic ductal adenocarcinoma.
Shares Multi-cancer early detection (MCED), Ovarian cancer, Pancreatic ductal adenocarcinoma.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
Shares Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late, Pancreatic ductal adenocarcinoma.
Shares FAPI PET, Ovarian cancer, Pancreatic ductal adenocarcinoma.
Shares A 28-day national pathway for people with a positive multi-cancer blood test, Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/